Resmetirom in children and teens with MASH

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 interventional study to evaluate the safety, pharmacokinetics, and pharmacodynamics of resmetirom in pediatric participants with metabolic dysfunction-associated steatohepatitis and liver fibrosis. Participants will receive oral resmetirom once daily for about 14 days at multiple dose levels to help determine appropriate dosing and assess biological effects. The study uses liver biopsy history and MRI-PDFF to select eligible participants and monitor hepatic fat content and drug exposure. Results will inform future pediatric dosing and safety considerations for resmetirom in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female participants 6 to 17 years of age, inclusive.
2. Parent(s) or legal guardian(s) able to provide written informed consent (as required by local regulations), with participant assent obtained as applicable.
3. Diagnose of MASH with fibrosis stage F1-F3 based on a liver biopsy obtained within 24 months before Screening.
4. Hepatic fat fraction ≥8% by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) obtained during the Screening period.
5. Able to swallow study tablets.
6. Females of childbearing potential must have a negative pregnancy test at screening, must not be pregnant or breastfeeding, and must agree to use a highly effective method of contraception during the study and for at least 30 days after the last dose of study drug. Premenarchal participants and those not of childbearing potential are eligible without contraception.

Exclusion Criteria:

1. Previous exposure to resmetirom.
2. Clinically significant liver disease other than MASH or evidence of cirrhosis (F4), decompensated liver disease, or other hepatic conditions that may interfere with study participation or interpretation of results.
3. Clinically significant thyroid disease or use of thyroid replacement therapy, triiodothyronine, thyroxine, or other prohibited thyroid medications.
4. Use of prohibited concomitant medications, including medications known to affect hepatic steatosis or liver function, lipid-lowering therapies, CYP2C8 inhibitors, OATP1B1/OATP1B3/BCRP inhibitors, protease inhibitors, St. John's Wort, or other medications prohibited by the protocol.
5. Use of glucagon-like peptide-1 (GLP-1) receptor agonists unless on a stable dose for at least 24 weeks before screening.
6. Clinically significant alcohol or substance abuse, or regular use of tobacco/nicotine products within 6 months before screening.
7. Active or clinically significant infection, including chronic hepatitis B or hepatitis C infection, HIV infection, or other immunocompromising conditions.
8. History or presence of clinically significant cardiovascular, pulmonary, renal, gastrointestinal, neurologic, hematologic, endocrine, psychiatric, or other medical conditions that, in the opinion of the Investigator, could interfere with study participation or interpretation of study results.
9. History of malignancy within the past 5 years (except adequately treated non-melanoma skin cancer or other protocol-permitted exceptions).
10. History of organ transplantation or known immunocompromised status.
11. Participation in another investigational study within 60 days or 5 half-lives (whichever is longer) before screening, unless permitted by the protocol.
12. Major surgery within 6 weeks before screening.
13. Known hypersensitivity to resmetirom or any excipient.
14. Females who are pregnant or breastfeeding.
15. Any condition that, in the opinion of the Investigator, would compromise participant safety, compliance, or the integrity of the study.

Where it's running

• Riley Hospital for Children at IU Health
  Indianapolis, Indiana, United States Recruiting

Study contacts

• Study coordinator: Tom Hare
• Email: info@madrigalpharma.com
• Phone: 267-406-0611

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digoxin for NASH with stage 2–3 fibrosis

  This trial will see if taking once-daily digoxin helps clear NASH and reduce liver scarring in adults with biopsy-confirmed NASH and stage 2–3 fibrosis.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT06588699

• Rezdiffra with diabetes and pioglitazone or dapagliflozin in adults with MASH and F2-F3 fibrosis

  This study tests whether Rezdiffra (resmetirom) can be safely used together with common diabetes medicines in adults with MASH and moderate to advanced liver fibrosis.

  Recruiting at 3 sites Phase 4 Madrigal Pharmaceuticals, Inc. · Chandler, Arizona and 15 other locations · NCT07848191

• Resmetirom for MASH with HFpEF in adults

  This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.

  Recruiting at 5 sites Phase 1 Madrigal Pharmaceuticals, Inc. · Peoria, Arizona and 4 other locations · NCT07830758

• MWN105 injection in overweight or obese adults you may join

  This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.

  Recruiting Phase 1 Shanghai Minwei Biotechnology Co., Ltd · Kunming, Yunnan · NCT07803809

• Liver Inflammation Index test for MASH in adults with T2DM and MAFLD

  This study tests a Liver Inflammation Index to see if it can identify MASH in adults who have both type 2 diabetes and MAFLD.

  Recruiting at 22 sites The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Bengbu, Anhui and 21 other locations · NCT07632677

• ALN-CIDEB for adults with fibrotic MASH (phase 2)

  This phase 2 study tests ALN-CIDEB versus placebo to see if it can reduce liver fat, injury, and scarring in adults with fibrotic MASH.

  Recruiting at 24 sites Phase 2 Regeneron Pharmaceuticals · Tucson, Arizona and 23 other locations · NCT07631637

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.